Skip to main content

ORIGINAL RESEARCH article

Front. Cardiovasc. Med.
Sec. Hypertension
Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1501296

Sex-Specific Differences in the Efficacy of Renal Denervation in Patients With Resistant Hypertension Depending on Visceral Obesity and Kidney Function

Provisionally accepted
Irina Vladimirovna Zyubanova Irina Vladimirovna Zyubanova *Nadezhda Ryumshina Nadezhda Ryumshina Victor Mordovin Victor Mordovin Musheg Manukyan Musheg Manukyan Valeriya Lichikaki Valeriya Lichikaki Ekaterina Solonskaya Ekaterina Solonskaya Anna Gusakova Anna Gusakova Tatiana E Suslova Tatiana E Suslova Stanislav Pekarskiy Stanislav Pekarskiy Simzhit Khunkhinova Simzhit Khunkhinova Anastasia Popova Anastasia Popova Veroniсa Rudenko Veroniсa Rudenko Alla Falkovskaya Alla Falkovskaya
  • Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia

The final, formatted version of the article will be published soon.

    Objective: To investigate the sex differences in the efficacy of renal denervation (RDN) in patients with resistant hypertension (RHT) concerning the size of abdominal fat depots, changes in biomarkers of sympathetic activity, and renal function.Materials and methods: 24 men (56.5±7.8 years) and 33 women (59.5±8.4 years) with RHT were enrolled in the study and underwent RDN. 24-hour ambulatory blood pressure (BP) (systolic/diastolic (SBP/DBP)), serum creatinine (with eGFR calculation), serum adipocytokines (leptin, adiponectin, resistin), serum metanephrines and normetanephrines were measured baseline and 12 months after RDN. The size of subcutaneous, visceral, and perirenal adipose tissue (SAT, VAT, and PRAT) was assessed using MRI.Results: After RDN, BP decreased, leptin increased, and adiponectin, resistin, and metanephrine levels did not change in both sexes. There was a decrease in normetanephrine levels in women and a similar trend in men.In men, the eGFR did not change. In women, the eGFR remained unchanged only in those with chronic kidney disease (CKD) (n=10) and decreased in the absence of CKD (n=23) from 79.7±14.1 to 72.1±12.0 ml/min/1.73m2 (p=0.011).Men had larger visceral fat depots, and women had larger subcutaneous fat depots. After RDN, the size of adipose tissue in men remained unchanged, and in women, the PRAT thickness decreased from 2.36±1.23 to 2.10±1.17 cm (p=0.002).Lowering BP in women was associated with increased leptin levels after RDN (r=-0.47 for SBP, r=-0.48 for DBP). Dependence of BP reduction on baseline eGFR was observed in men only (r=0.44 for SBP, r=0.48 for pulse pressure (PP)).Additionally, in men, the decrease in SBP and PP depended on VAT areas (r=-0.44 and r=-0.58, respectively). In women, the SBP reduction showed an inverse correlation between baseline weight (r=-0.35) and waist circumference (r=-0.38).The magnitude of the antihypertensive effect of RDN depends on signs of visceral obesity and, in men, also on the presence of CKD. Renoprotective effects of RDN in men are obtained regardless of the initial kidney function, while in women, it was observed only in individuals with CKD. Additional beneficial effects of RDN in women include a decrease in normetanephrine levels and a reduction in PRAT size.

    Keywords: renal denervation, Resistant hypertension, Responders, Visceral obesity, Perirenal fat, Renal function, Chronic Kidney Disease

    Received: 24 Sep 2024; Accepted: 15 Jan 2025.

    Copyright: © 2025 Zyubanova, Ryumshina, Mordovin, Manukyan, Lichikaki, Solonskaya, Gusakova, Suslova, Pekarskiy, Khunkhinova, Popova, Rudenko and Falkovskaya. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Irina Vladimirovna Zyubanova, Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.